CHICAGO—Findings from a Phase III trial show that initial single-agent therapy with a new oral drug called afatinib prolongs progression- free survival in patients with advanced lung adenocarcinomas t
James Yang
CHICAGO—Findings from a Phase III trial show that initial single-agent therapy with a new oral drug called afatinib prolongs progression- free survival in patients with advanced lung adenocarcinomas that harbour EGFR mutations, compared with current standard treatment. Afatinib broadly blocks the ErbB family receptors associated with the EGFR pathway; patients with two specific types of EGFR mutations experienced the greatest treatment benefit. James Yang MD, PhD of the National Taiwan University Hospital in Taipei discussed the findings with Peter Goodwin.
LISTEN
[audio:https://www.audiomedica.com/podcasting/news/120611JamesYangINTERVIEWLoRes.mp3]
Related Episodes
Jefferson DeKloe BSc: Big US Study Confirms Benefit of HPV Vaccination for Boys as Well as Girls
The cancer prevention benefit of vaccination against the human papilloma virus cancer prevent are slowly accruing thanks to European, American and other population-based studies. I’m Peter Goodwin wi
Luis Paz-Ares MD PhD: Longer Survival Among Patients with Extensive Stage Small Cell Lung Cancer Treated with Lurbinectedin Maintenance —ASCO 2025
Luis G Paz-Ares MD PhD discdusses the addition of lurbinectedin as maintenance therapy for extensive stage small cell lung cancer (SCLC)
Frank A Sinicrope MD: Stage 3 Colon Cancer with Deficient Mismatch Repair: Big Gains from Atezolizumab Added to Standard Chemotherapy
An interview with: Frank A Sinicrope, MD, Medical Oncologist, Mayo Clinic, Rochester, Minnesota. CHICAGO —Big gains in survival have been reported among patients with stage three, node-positive colon